Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Separation or purification
Reexamination Certificate
2006-02-14
2006-02-14
Low, Christopher S. F. (Department: 1614)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Separation or purification
C530S413000, C530S414000, C530S417000
Reexamination Certificate
active
06998470
ABSTRACT:
The present invention relates to a method of isolating and/or purifying hypothalamic inhibitory factor (HIF) from a sample (e.g., tissue fluid) containing HIF. The present invention provides for isolation of large amounts of HIF using diafiltration, solid phase extraction and immunoaffinity techniques. In one embodiment, the invention relates to a method of purifying hypothalamic inhibitory factor from a sample containing hypothalamic inhibitory factor comprising subjecting the sample to diafiltration, solid phase extraction and immunoaffintiy chromatography. In a particular embodiment, the invention relates to subjecting the sample to diafiltration to produce a diafiltrate of HIF; subjecting the diafiltrate to a first solid phase extraction (SPE) to produce a first fraction of HIF; subjecting the first fraction to immunoaffinity chromatography, wherein an antibody which binds to HIF is coupled to an immunoaffinity column, to produce a second fraction of HIF; subjecting the second fraction of HIF to reverse phase HPLC chromatography to produce a third fraction of HIF; and recovering purified HIF from the third fraction.
REFERENCES:
patent: 4551426 (1985-11-01), Freytag et al.
patent: 4665019 (1987-05-01), Hamlyn et al.
patent: 4780314 (1988-10-01), Graves
patent: 4897465 (1990-01-01), Cordle et al.
patent: 5164296 (1992-11-01), Blaustein et al.
patent: 5429928 (1995-07-01), Blaustein et al.
patent: 5716937 (1998-02-01), Haupert, Jr.
patent: WO92/04047 (1992-03-01), None
Sergio, B. et al., “Effects of an Endogenous Ouabainlike Compound on Heart and Aorta”,Hypertension, 17(6): Part 2:944-950 (1991).
Mathews, W.R. et al., “Mass Spectral Characterization of an Endogenous Digitalis-Like Factor From Human Plasma”,Hypertension, 17(6): Part 2:930-935 (1991).
Ludens, J.H. et al., “Purification of an Endogenous Digitalis-like Factor From Human Plasma for Structural Analysis”,Hypertension, 17(6): Part 2: 923-929 (1991).
Hamlyn, J.M. et al., “Identification and Characterization of a Ouabain-like Compound from Human Plasma”,Proc. Natl. Acad. Sci. USA, 88:6259-6263 (1991).
Haber, E. and Haupert, Jr., G.T., “The Search for a Hypothalamic Na, K-ATPase Inhibitors”,Hypertension, 9:315-324 (1987).
Haupert, Jr., G.T., “Overview: Physiological Inhibitors of Na, K-ATPase Concept and Status”,The Na+,K+—Pump Part B: Cellular Aspects, 297-320 (1988).
Mudgett-Hunter, M. et al., “High-Affinity Monoclonal Antibodies to the Cardiac Glycoside, Digoxin”,J. Immunol., 129(3):1165-1172 (1982).
Carilli, C.T. et al., “Hypothalamic Factor Inhibits the (Na, K)ATPase from the extracellular Surface”,J. Biol.Chem., 260(2):1027-1031 (1985).
Janssens, S.P. et al., “Hypothalamic Na+, K+-ATPase Inhibitor Constricts Pulmonary Arteries of Spontaneously Hypertensive Rats”,J. Cardio. Pharm., 22(Suppl. 2):S42-S46 (1993).
Haupert, Jr., G.T. and Sancho. J.M., “Sodium transport inhibitor from bovine hypothalamus”,Proc. Natl. Acad. Sci. USA, 76(9):4658-4660 (1979).
Haupert, Jr., G.T. et al., “Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na+-K+-ATPase”, reprint fromAm. Physiol. Soc, 247:F919-F924 (1984).
Mirsalikhova, N.M. et al., “Some Features of the Inhibition of Na+, K+-ATPase in Heart Muscle by Cardiotonic Glycosides”,Inst. Biochem. and Inst. Chem. Plant Subst., Academy of Sciences of the Urbek SSR, Tashkent, USSR, p. 269-275.
Pitts, R.F., “Chapter 5, Clearance and Rate of Glomerular Filtration”,Physiology of the Kidney and Body Fluids(Year Book Medical Publishers Inc., 3rd Edition, Chicago, IL):60-63.
Mudgett-Hunter, M. et al., “Binding and Structural Diversity Among High-Affinity Monoclonal Anti-Digoxin Antibodies”,Mol. Imunol., 22(4):477-488 (1985).
Smith, T.W. et al., “Treatment of Life-Threatening Digitalis Intoxication with Digoxin-Specific Fab Antibody Fragments”,The New England Journal of Medicine, 307(22):1357-1362 (1982).
Smith, T.W. et al., “Reversal of Advanced Digoxin Intoxication with Fab Fragments of Digoxin-Specific Antibodies”,The New England Journal of Medicine, 294(15):797-800 (1976).
Hallaq, H.A. and Haupert, Jr., G.T., “Positive inotropic effects of the endogenous Na+/K+-transporting ATPase Inhibitor form the hypothalamus,”,Proc. Natl. Acad. Sci. USA, 86:10080-10084 (1989).
Axelrod, J., “J. Methylation reactions in the Formation and Metabolism of Catecholamines and Other Biogenic Amines”,Pharm. Rev., 18(1):Part I:95-113 (1966).
Thomas, R. et al., “Synthesis and Biological Activity of Semisynthetic Digitalis Analogs”,J. Pharm. Sci., 63(11):1649-1683 (1974).
Hoffman, B.F. and Bigger, Jr., J.T., “Chapter 34: Digitalis and Allied Cardiac Glycosides”,The Pharmacological Basics for Therapeutics, (NY: Pergamon Press):814-839 (1990).
Haupert, Jr., G.T. et al. “Target Organ Sensitivity to an Endogenous Na, K-ATpase Inhibitor from Hypothalamus”,Kidney Int., 31:435A (1987).
Weinberg, U. et al., “Identification and Preliminary Characterization of Two Human Digitalis-Like Substances that are Structurally Related to Digoxin and Ouabain”,Biochem.&Biophys. Res. Comm., 188(3):1024-1029 (1992).
Tamura, M. et al., “Isolation and Characterization of a Specific Endogenous Na+, K+-ATPase Inhibitor from Bovine Adrenal”,Biochem., 27:4244-4253 (1988).
Schoner, W. et al., “Purification and Properties of Endogenous Ouabain-like Substances from Hemofiltrate and Adrenal Glands”,J. Cardiovas. Pharm., 22(Suppl. 2):S29-S31 (1993).
Lewis, L.K. et al., “Ouabain Is Not Detectable in Human Plasma”,Hypertension, 24(5):549-555 (1994).
Valdes, Jr., R. & Graves S.W. “Protein Binding of Endogenous Digoxin-Immunoactive Factors in Human Serum and Its Variation with Clinical Condition”,J. Clin. Endoc. Metab., 60(6):1135-1143 (1985).
Illescas, M. et al., “Complete purification of two identical Na+-pump inhibitors isolated from bovine hypothalamus and hypophysis”,FEBS Let., 261(2):436-440 (1990).
Zhao,N. et al., “Na,K-ATPase Inhibitors from Bovine Hypothalamus and Human Plasma Are Different from Ouabain: Nanogram Scale CD Structural Analysis”,Biochem., 34:9893-9896 (1995).
Tymiak et al., “Physicochemical Characterization of a Ouabain Isomer Isolated from Bovine Hypothalamus”,Proc. Natl. Acad. Sci., 90:8189-8193 (1993).
Nakanishi et al., “Search for an Endogenous Mammalian Cardiotonic Factor”,Saponins Used in Traditional and Modern Medicine, pp:219-224 (1996).
Anner et al., “Hypothalamic Na+-K+-ATPase Inhibitor Characterized in Two-Sided Liposomes Containing Pure Renal Na+-K+-ATPase”,Am. J. Physiol., 258(Renal Fluid Electrolyte Physiol., 27):F144-F153 (1990).
Montali, U., et al., “Purification of Endogenous Digitalis-Like Factor(s) from Cord Blood of Neonate by Immunoaffinity Chromatography,”Biochem. Int;25:853-859 (1991).
Gallagher Rex T.
Haupert, Jr. Garner T.
Bion, Inc.
Delacroix-Muirheid C.
Hamilton Brook Smith & Reynolds P.C.
Low Christopher S. F.
The General Hospital Corp.
LandOfFree
Process for large-scale isolation and purification of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for large-scale isolation and purification of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for large-scale isolation and purification of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3647833